Antigen-induced Pleural Eosinophilia is Suppressed in Diabetic Rats: Role of Corticosteroid Hormones

Bruno L Diaz, Magda F Serra, Emiliano O Barreto, Renato SB Cordeiro, Marco A Martins, Patricia MR e Silva

Laboratório de Inflamação, Departamento de Fisiologia e Farmacodinâmica, Instituto Oswaldo Cruz, Av. Brasil 4365, 21045-900 Rio de Janeiro, RJ, Brasil

Previous studies have evidenced for the existence of interactive regulatory mechanisms between insulin and steroid hormones in different systems. In this study, we have investigated whether endogenous corticosteroids could be implicated in the hyporeactivity to antigen challenge observed in sensitized diabetic rats. Alloxinated rats showed a long-lasting increase in the blood glucose levels and a reduction in the number of pleural mast cells at 48 and 72 hr, but not at 24 hr after alloxan administration. In parallel, they also showed a significant elevation in the plasma levels of corticosterone together with an increase in the adrenal/body weight ratio. Antigen-evoked eosinophil accumulation appeared significantly reduced in rats pretreated with dexamethasone as well as in those rendered diabetic 72 hr after alloxan. In the same way, naive animals treated with dexamethasone also responded with a significant decrease in the number of pleural mast cells. Interestingly, when sensitized diabetic rats were pretreated with the steroid antagonist RU 38486 a reversion of the reduction in the allergen-induced eosinophil accumulation was noted. We conclude that the down-regulation of the allergic inflammatory response in diabetic rats is close-related to reduction in mast cell numbers and over expression of endogenous corticosteroids.

Key words: diabetes - allergic pleurisy - mast cells - eosinophils - corticosteroids

Diabetes is a metabolic disorder in which there is an impairment of glucose utilization caused by a derangement in insulin function. Thus, hyperglycemia concomitant with other metabolic disfunctions as peripheral insulin resistance are characteristic features of this disease (WHO Study Group 1985). Studies in experimental animals and investigations in diabetic individuals demonstrated their fail in mounting a properly inflammatory reaction, though the precise mechanism underlying this phenomenon is still unknown. There are some pieces of evidence demonstrating that diabetics show alterations in the microcirculatory reactivity as well as functional abnormalities in leucocyte functions (LLorach et al. 1976, Pereira et al. 1987). Previous studies reported that diabetics may show hypertrophy of the adrenal cortex concomitant with an increase in the adrenal steroid production (Kraus 1973). Glucocorticoids have long been known as powerful anti-inflammatory compounds which have an important modulatory effect on different cell types including mast cells and eosinophils (reviewed in Schleimer 1990). In a variety of species, treatment with glucocorticoid effectively prevented infiltration of eosinophils into local tissue sites after antigen stimulation (Sanjar et al. 1990, Sullivan et al. 1994). We have recently reported that rats with alloxan diabetes show a reduction in the pleural mast cell population and also a suppression of the antigen-induced pleural eosinophilia, phenomena clearly sensitive to insulin treatment (Diaz et al. 1996). The purpose of this study was to investigate the relationship between endogenous corticosteroids and the pleural mastocytopenia as well as the hyporeactivity to antigen challenge in alloxan diabetic rats.

MATERIALS AND METHODS

Male Wistar rats from the Oswaldo Cruz Foundation breeding were used and diabetes was induced by a single injection of alloxan monohydrate (Sigma St. Louis, USA) (40 mg/kg, i.v.;) into 12 hr fasted rats. Control animals were injected with vehicle and submitted to similar experimental conditions. In another set of experiments, alloxan was injected 24, 48 or 72 hr before antigen challenge.
Corticosteroids and Hyporeactivity in Alloxan Diabetes • BL Diaz et al.

in sensitized rats. Glucose concentration was determined spectrophotometrically in whole blood and only rats with glucose levels above 200 mg/dl were considered in further experiments. Active sensitization was performed subcutaneously with ovalbumin (OVA; Fluka Chemie AG, Switzerland) (50 µg) and Al(OH)3 (5 mg) and 14 days later, the animals were challenged with an intrapleural (i.pl.) injection of OVA (12 µg/cavity). Pleurisy was evaluated as previously described (Silva et al. 1992). Total and differential leucocyte counts were performed in an automatic cell counter and in cytospin preparations stained with May-Grunwald-Giemsa dye, respectively. Mast cells were stained with toluidine blue and counted in a Neubauer chamber. Plasma corticosterone levels were determined using a radioimmunoassay (ICN Pharmaceuticals), and both adrenal glands were dried for 24 hr at 40°C and weighed. Dexamethasone (Prodrome, Brazil) was administered either 1 hr before antigen (0.5 mg/kg) or once a day during three days (0.1 mg/kg) in the case of naive rats. The steroid antagonist RU38486 (11ß-(4-dimethyl amino-phenyl)17ß-hydroxy, 17α(prop-1-ynyl) estra 4,9-dien-3-one; a kind gift from Roussel-Uclaf, Romainville, France) was administered orally (20 mg/kg) 2 hr before the alloxan injection and twice a day during two days following diabetes induction. The data were statistically analyzed by ANOVA followed by the Newman-Keuls-Student’s t test and values of 0.05 or less considered significant.

RESULTS

We observed that intravenous administration of alloxan (40 mg/kg) into rats led to a progressive increase in the blood glucose concentration, maximal at three days (Fig. 1A). In parallel, a selective reduction in the number of mast cells recovered from the pleural cavity was noted at 48 and 72 hr, but not at 24 hr after alloxan, lasting for at least 60 days (Fig. 1A). Alloxinated rats also showed an elevation in the plasma corticosterone levels (Fig. 1B) as well as in the ratio of combined adrenal glands/body weight at 72 hr after diabetes induction. Ratio values were 0.043 ± 0.004 (mean ± SEM) (n=6) in controls and 0.104± 0.008 in diabetic animals (n=7) (p<0.001). Experiments were further performed to evaluate whether the reduction in the pleural mast cell population noted in diabetic rats might influence the antigen-induced eosinophilia. As illustrated in Fig. 2, sensitized rats rendered diabetic 48 and 72 hr but not 24 hr before, showed a less pronounced eosinophil accumulation when compared to sensitized non-diabetics. In addition, we verified that treatment of sensitized rats with dexamethasone (0.5 mg/kg, i.p.) 1 hr before the ovalbumin, markedly inhibited the eosinophilia noted 24 hr-post challenge. The number of eosinophils decreased from 16.74 ± 2.47 x 10⁶ cells/cavity (mean ± SEM) (n=8) in controls to 2.07 ± 0.35 x 10⁶ cells/cavity in treated animals (n=8) (p<0.001). When dexamethasone (0.1 mg/kg) was administered into naive rats once a day, during three days, a significant reduction in the number of pleural mast cells was noted, values decreasing from 583.8 ± 27.9 x 10³ cells/cavity (mean ± SEM) (n=8) in controls to 311.3 ± 24.8 x 10³ cells/cavity (n=8) (p<0.001) in treated rats. The involvement of endogenous corticosterone in the hyporeactivity to allergen challenge in diabetics was further investigated by treating the animals with the steroid antagonist compound RU38486. Sensitized diabetic rats treated with RU38486 (20 mg/kg) showed a significant reversion of the decrease in the allergen-induced eosinophil accumulation (Fig. 3).
DISCUSSION

Diabetics hardly exhibit typical inflammatory reaction, a phenomenon associated with the development of the diabetic state, but independent of alterations in the peripheral blood leucocytes and cellular glucopenia. In this study, we demonstrated that rats rendered diabetic after alloxan administration showed a significant increase in the blood glucose levels already detected 24 hr after alloxan, and also that the eosinophil accumulation triggered by antigen in the rat pleural cavity was clearly suppressed in the 48- and 72-hr but not 24-hr diabetic animals. Our data are in accordance with a previous study which demonstrated the reduction in the number of eosinophils in the bronchoalveolar lavage recovered from sensitized diabetic rats (Vianna & Garcia-Leme 1995). It is noteworthy that the chemotactic response of diabetic eosinophils to PAF or LTB₄ in vitro did not differ from that of normal eosinophils (data not shown), indicating the absence of an intrinsic abnormality in the locomotory function of these cells. Interestingly, in parallel to the above mentioned diabetes alterations, alloxinated rats also showed a selective reduction in the number of pleural mast cells, first noted within 48 hr and lasting for at least 60 days. Similarly, Casacó et al. (1990) demonstrated that alloxan-treated rats showed a reduction in the number of mast cells in peritoneal cavity and a clear resistance to the lethal effect of the compound 48/80. We have also verified a close relationship between the time course of the reduction in the number of mast cells and the subsequent refractoriness to antigen-induced eosinophil accumulation, which was noted in rats rendered diabetics 48 and 72 hr but not 24 hr before. These data are consistent with the interpretation that alterations in the mast cell population may contribute to the hyporeactivity associated with diabetic state.

Though the relationship between glucocorticoids and diabetes has not been completely elucidated, it has been proposed that in the diabetes the regulation of factors controlling adrenal steroid secretion and metabolism may be altered (Wexler & Lutmer 1975, Meehan et al. 1986). We have found that 72 hr-alloxinated rats showed higher levels of plasma corticosterone and an increase in the adrenal gland/body weight ratio, confirming previous reports (Lentle & Thomas 1964, Wexler & Lutmer 1975, Cameron et al. 1987, Fitzpatrick et al. 1992). These alterations in diabetes may probably be dependent on changes in the steroid feedback controlling mechanisms in the hypothalamic-pituitary-adrenocortical system. Glucocorticoids have been demonstrated to induce significant reduction in the number as well as in the secretory response of mast cells (Sim et al. 1992). Thus, we have further evaluated the effect of exogenous steroids on the eosinophil accumulation noted after antigen. Pretreatment with dexamethasone suppressed the allergic pleural eosinophilia and was also effective in diminishing the pleural mast cell population in naive rats. Exposure of eosinophils to dexamethasone did not affect their chemotactic response to PAF and LTB₄ in vitro (not shown), suggesting that the glucocorticoids may be acting on an intermediate step of eosinophil recruitment.
probably blocking the synthesis and/or secretion of chemoattractants. Alternatively, glucocorticoids may be acting in the post-capillary venules to impair cell extravasation. Besides testing the effect of dexamethasone, we have also evaluated the involvement of endogenous corticosteroids in hyporeactivity to allergen challenge associated with diabetic state. The oral treatment of sensitized diabetic rats with the steroid receptor antagonist RU38486 (or mifepristone) reversed the reduced eosinophil accumulation, indicating a role for glucocorticoids in this phenomenon. We have reported that insulin treatment was able to reverse the suppression of allergic eosinophilia in diabetic rats (Diaz et al. 1996). Thus, considering that glucocorticoids and insulin are opposing biological effects in several systems (Garcia-Leme & Farsky 1993), it is valid to speculate that the balance between systemic levels of these hormones may be important to determine the intensity of allergic eosinophilic response.

In conclusion, we demonstrate that the reduction in the antigen-induced eosinophil accumulation noted in alloxan diabetic rats shows a close relationship with the decrease in the mast cell population and the augmentation in the levels of endogenous corticosteroids.

ACKNOWLEDGMENTS

To Mr Edson Alvarenga for his technical assistance.

REFERENCES


